HIV Vaccines—Key Messages
HIV Vaccine Awareness Day
May 2020

For more on the state of HIV vaccine research and advocacy, please visit: www.avac.org/hvad

On HIV Vaccine Awareness Day, the need for an HIV vaccine is as great as ever.

- Even with highly effective treatment, and proven prevention methods such as PrEP, most recent data show an estimated 1.7 million people around the world still became newly infected with HIV.
- In many communities, such as adolescent girls and young women in sub-Saharan Africa, people who inject drugs and young men who have sex with men, HIV infection rates are still high, or climbing.
- A vaccine is needed for a durable and sustainable end of the HIV epidemic.

HIV vaccine research is on a strong path forward, with several large trials underway and dozens of new approaches in development.

- Two large efficacy trials, Imbokodo and Mosaico, are testing mosaic-based vaccine regimens, designed to protect against a wide variety of HIV sub-types.
- The PrEPVacc study will test two vaccine regimens and compare two daily oral PrEP regimens.
- Two antibody-mediated prevention (AMP) studies will report later in 2020 whether infusions of a broadly neutralizing antibody against HIV can protect against infection.
- Dozens of additional HIV vaccine approaches are in pre-clinical and clinical studies.
- While the early stop to vaccinations in the HVTN 702 vaccine study was a setback this year, what is learned from that study can make future HIV vaccine research efforts smarter and stronger.

As progress towards an HIV vaccine continues, HIV vaccine research discoveries, funding collaboratives and trial networks are also speeding global responses to COVID-19.

- Community engagement strategies such as the AVAC/UNAIDS Good Participatory Practice (GPP) Guidelines, adapted for emerging pathogens by WHO, are strengthening community involvement in research and can support efforts to ensure equitable global access to COVID-19 treatments and vaccines in development.
- Community-led health education models pioneered in HIV are also working to counter COVID-19 stigma and misinformation, and hold political leaders accountable in the global response.